Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lupus nephritis

M M Schwartz1

  • 1Department of Pathology, Rush Medical College, Chicago, Illinois, USA.

Current Opinion in Nephrology and Hypertension
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Lupus nephritis, a severe complication of systemic lupus erythematosus, is diagnosed using renal biopsy and clinical signs. New research explores antibodies and antigens for better understanding and treatment of this kidney disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis.

Lupus·2009
Same author

Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis.

Lupus·2006
Same author

Pathology of lupus nephritis.

Lupus·2005
Same author

Severe lupus nephritis: importance of re-evaluating the histologic classification and the approach to patient care.

Journal of nephrology·2001
Same author

Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.

Kidney international·2001
Same author

The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis.

Renal failure·2000
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
See all related articles

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Lupus nephritis significantly impacts patient morbidity and mortality.
  • Renal biopsy pathology and clinical features are key prognostic and therapeutic indicators.
  • Serologic markers correlate with disease activity, with potential pathogenetic implications from cationic and anti-endothelial cell antibodies.

Purpose of the Study:

  • To review current understanding of lupus nephritis pathogenesis and treatment.
  • To highlight the transfer of experimental findings on pathogenic mechanisms to clinical settings.
  • To assess recent therapeutic trials and identify gaps in evidence.

Main Methods:

  • Review of pathological findings and clinical features in lupus nephritis.
  • Analysis of serologic markers, including cationic and anti-endothelial cell antibodies.

Related Experiment Videos

  • Evaluation of experimental studies and recent clinical therapeutic trials.

    • Main Results:

    • Pathology and clinical presentation remain crucial for prognosis and treatment guidance.
    • Cationic nuclear antigens, cationic antibodies, and anti-idiotypic antibodies show pathogenetic relevance.
    • Experimental findings are increasingly supported by clinical observations in humans.
    • Current therapy relies on nonspecific immunosuppression, with limited controlled therapeutic trials.

    Conclusions:

    • Understanding pathogenic mechanisms, including antibody roles, is advancing lupus nephritis treatment strategies.
    • Further controlled clinical trials are necessary to establish effective new therapies.
    • Integrated insights from pathology, serology, and experimental models are vital for improving patient outcomes.